Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Will Distribution Practices Be Improved? Part 5 (Final)
October 13, 2008
- Lantus Lowers HbA1C and Is Cost-Effective: sanofi-aventis
October 13, 2008
- BUSINESS NEWS IN BRIEF
October 13, 2008
- Heart Failure Can Be Prevented by Controlling BP: Prof. Komuro
October 13, 2008
- Takeda Applies for Alogliptin without Conducting PIII in Japan
October 13, 2008
- Prevention of Locomotor Disorders Urgently Required: JOA
October 13, 2008
- Korosho to Survey Code Labeling of Drugs
October 13, 2008
- 97% of Hospitals Protect ED Patient Privacy: Lilly Survey
October 13, 2008
- Companies Must More Quickly Decide Development to Eliminate Drug Lag: Mr Sato
October 13, 2008
- Change Mindset from Treatment to Prevention: Dr R.H. Carmona
October 13, 2008
- NCVC to Switch Top 150 Original Drugs to Generics
October 13, 2008
- Bayer to Expand Women's Healthcare Business
October 13, 2008
- Drug Lag Attributable to Delay in Starting Clinical Trials: OPIR Study
October 13, 2008
- REGULATORY NEWS IN BRIEF
October 13, 2008
- NEW PRODUCTS
October 13, 2008
- Original and Generic Amlodipine Products Show Same Effects
October 13, 2008
- Kyowa Hakko Kirin Sets Out Aiming at Becoming Global Specialty Pharma
October 13, 2008
- GENERICS NEWS IN BRIEF
October 13, 2008
- SELF-MEDICATION NEWS IN BRIEF
October 13, 2008
- RAD001 Prolongs PFS in Patients with RCC: Novartis
October 13, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…